ArticleWorld journal of clinical oncology2025
Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.The oncologist · 2026Article
- Vitamin D and adverse pathologic features in patients undergoing radical prostatectomy in the contemporary magnetic resonance imaging-guided management era.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D deficiency has been associated with prostate cancer, particularly in ethnic minorities. Patients with prostate cancer may still be deficient even in areas of high sun exposure. Although androgen deprivation therapy (ADT) is well documented to affect bone health, its impact on vitamin D levels is still uncertain. This study investigates the subgroups of prostate cancer patients most associated with vitamin D deficiency and ADT's relation to this.
aimTo examine how prevalent vitamin D deficiency is among prostate cancer patients in a sun-rich environment, with focus on differences by race and disease stage. It also assessed whether ADT is associated with changes in vitamin D levels.
methodsProstate cancer patients treated at Chao Family Comprehensive Cancer Center between 2014-2024 were retrospectively studied with regards to vitamin D levels across racial groups, disease stages, and ADT exposure. Changes in vitamin D levels pre- and post-ADT over 24 months were assessed by statistical methods including paired
resultsAmong 120 patients (mean age: 74 years, mean body mass index: 27.6 kg/m²), African American (33.3%) and Hispanic (31.8%) patients had the greatest prevalence of vitamin D deficiency (< 20 ng/mL). With a 28.6% deficit rate, metastatic castration-resistant prostate cancer had the highest prevalence rates of deficiency. There was no significant difference between pre- and post-ADT vitamin D levels (
conclusionVitamin D deficiency is common in prostate cancer patients, especially racial minorities and those with advanced disease, despite residing in an area with high sun exposure. ADT does not significantly impact vitamin D levels in the short term. Routine screening and supplementation should be considered in these high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.